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ABSTRACT
Patients with primary mediastinal nonseminomatous germ cell tumors have a poor prognosis, with a 5-year
overall survival of nearly 50%. We investigated the feasibility and activity of early high-dose chemotherapy
(HDCT) in these patients. After conventional induction chemotherapy, patients underwent a single shot of
HDCT consisting of carboplatin, etoposide, and cyclophosphamide, followed by peripheral blood progenitor
cell support. Twenty-one patients were considered for treatment with HDCT.Median age was 29 years (range,
19-55 years). Eight (38%) patients had lung metastases. After primary chemotherapy, 7 patients achieved
complete remission, 4 achieved partial remission with negative marker, 1 achieved partial remission with
positive marker, 2 had stable disease, and 7 progressive disease. Twelve patients were not treated with HDCT
due to progressive disease and poor physical conditions. No HDCT-related deaths or irreversible organ
toxicities were observed. Residual surgery after HDCT was performed in 4 patients and resulted in 3
pathologic complete remissions. With a median follow-up of 52 months (range, 15-71 months) in 9 patients
treated with HDCT, 8 have been continuously free of disease. Of 12 patients who did not receive HDCT, 0 was
alive at 2 years from diagnosis. A single course of HDCT after induction chemotherapy appeared to be
inapplicable in most of our patients, mainly due to early progressive disease. These data should be considered
in the analysis of retrospective series and in the design of new prospective trials with HDCT in these patients.
Earlier HDCT administration followed by residual surgery should be considered for further investigation.
© 2006 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Although patients with advanced testicular germ
ell malignancies present a high cure rate, patients
ith primary mediastinal nonseminomatous germ cell
umor (PMNSGCT) have a poor prognosis [1,2]. The
-year overall survival (OS) rate is nearly 50%, and the
-year disease-free survival rate approximately 40%
or these patients after conventional-dose cisplatin and
toposide-based chemotherapy and surgery, if neces- sary [1,2]. The presence of lung metastases represents
nother unfavorable prognostic factor [3,4].
High-dose chemotherapy (HDCT) with periph-
ral blood progenitor cell (PBPC) support has been
nvestigated, with controversial results in these pa-
ients [5-9]. Recently, multicycle upfront HDCT has
hown interesting results in these patients [10].
We investigated the feasibility and activity of an
arly single HDCT course with carboplatin, etopo-
ide, and cyclophosphamide (the CARBOPEC regi-
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G. L. Banna et al.1086en) with PBPC support in patients who did not
rogress to standard-dose cisplatin and etoposide-
ased chemotherapy.
ETHODS
atients
All patients with PMNSGCT who were followed
t the Istituto Clinico Humanitas (Milan, Italy) and
he Istituto Oncologico Romagnolo (Ravenna, Italy)
etween 1993 and 2004 were prospectively enrolled.
ritten informed consent was obtained. No prior
reatments were allowed. In the absence of histologic
iagnosis (due to the need for urgent chemotherapy
reatment or difﬁculty in obtaining an adequate bi-
psy), high serum levels of -human chorionic gonad-
tropin (-hCG) and/or -fetoprotein (AFP) and/or
actate dehydrogenase (LDH) with a clinical picture
nd staging compatible with PMNSGCT were ac-
epted.
Evaluation before chemotherapy included a de-
ailed history, full physical examination, chest radio-
raph, computed tomography of the thorax, abdomen,
nd pelvis, standard hematologic and biochemical pa-
ameters, and measurement of serum tumor markers
AFP, -hCG, and LDH). Computed tomography or
agnetic resonance imaging of the brain and radio-
uclide bone scan were performed in symptomatic
atients.
reatment
Induction chemotherapy consisted of cisplatin,
toposide, and bleomycin (PEB) or ifosfamide (VIP).
hemotherapy was given if neutrophil and platelet
ounts were 500/L and 100 000/L, respec-
ively, at day 1 of each course. Prophylactic adminis-
ration of granulocyte colony-stimulating factor (G-
SF) was used for all subsequent chemotherapy
ourses in case of neutropenic fever during 1 preced-
ng course.
Responding patients underwent PBPC mobiliza-
ion preferentially with cyclophosphamide 4.5 g/m2
lus G-CSF 5 g/kg per day or G-CSF 10 g/kg per
ay alone. After chemotherapy, G-CSF was started
-2 days after cessation of chemotherapy and was
ontinued until the day of PBPC harvesting. PBPCs
ere harvested with a Cobe Spectra (Denver, CO,
SA) 3000 device, and the targeted dose was ﬁxed at
 106 CD34 cells/kg.
All patients undergoing HDCT were required to
ave an Eastern Cooperative Oncology Group perfor-
ance status of 0-1, no prohibitive medical comor-
idities, and no progressive disease after induction
hemotherapy. HDCT consisted of carboplatin at a
ose of 250, 400, or 550 mg/m2 intravenously on days
6 to 3, if creatinine clearance was 30-59, 60-100, wr 100 mL/min, respectively; etoposide 450 mg/m2
ntravenously on days 6 to 3; and cyclophospha-
ide 1600 mg/m2 intravenously on days 6 to 3,
ith mesna 1600 mg/m2 intravenously over 24 hours
f continuous infusion on days 7 to 1 (CARB-
PEC regimen). On day 0, PBPCs were reinfused
ollowed by G-CSF 5 g/kg per day from day 1
ntil hematologic recovery.
All patients with residual radiographic disease af-
er completion of induction chemotherapy were eval-
ated for complete residual surgery before undergoing
DCT. Patients who were deemed not operable by
he surgeons underwent HDCT and were subsequently
eassessed for surgery in case of disease persistence.
esponse Evaluation
After induction chemotherapy and after HDCT,
umor response was evaluated by computed tomogra-
hy of the chest, abdomen, and pelvis and by mea-
urement of serum tumor markers. After treatment
as completed, patients were followed up every 3
onths in the ﬁrst year, every 4 months in the second
nd third years, every 6 months up to 5 years, and
nnually thereafter. Tumor response was classiﬁed as
ollows. Clinical complete remission (cCR) was de-
ned as complete disappearance of all clinical, radio-
ogic, and biochemical evidence of disease, with nor-
alization of levels of tumor markers (-hCG and/or
FP and/or LDH) for 1 month. A partial response
PR) was deﬁned as a decrease 50% of the sum of
he products of perpendicular diameters of measurable
isease that lasted 1 month. In addition, patients
ith PR and normalization of previously elevated tu-
or marker levels were classiﬁed as tumor-marker-
egative partial responders (PRm) and those with
90% decrease in markers but without normalization
s tumor-marker-positive partial responders (PRm).
table disease (SD) was deﬁned as a decrease50% or
n increase 25% in bidimensional tumor measure-
ents or stable tumor marker levels. After complete
esidual surgery, patients with normal tumor marker
evels were deﬁned as having pathologic complete
emission (pCR) if necrosis/ﬁbrosis and/or mature
eratoma was histologically proved, or surgical com-
lete remission (sCR) when viable malignant tumor
ells were documented. Disease progression (PD) was
eﬁned as residual lesions increasing in size or as the
ccurrence of new tumor lesions and/or serial eleva-
ion of tumor markers at repeated controls.
Treatment-related toxicity was assessed with NCI-
TC 2.0 (National Cancer Institute, Bethesda, Md).
tatistical Analysis
The study was planned as a 2-stage design accord-
ng to the design of Simon [11]. Alpha and beta errors
ere set at 10%. A response rate 15% was consid-
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High-Dose Chemotherapy for Mediastinal Germ Cell Tumors 1087red to be of interest, and 19 patients were entered in
he ﬁrst stage. If no responses were noted in the ﬁrst
tage, that arm would be terminated. Otherwise, if 1
esponse was noted, an additional 18 patients needed
o be accrued for a total of 37 patients. Data were
ollected retrospectively into a database and are pre-
ented as number and proportion or as median and
ange, where appropriate. Progression-free survival
PFS) and OS curves were generated with Kaplan-
eier statistical analysis [12]. PFS time was calculated
rom enrollment to progression. OS time was calculated
rom enrollment to death or last contact. All analyses
ere made with Statistica 6.0 (www.statsoft.com).
ESULTS
atients and Treatment
Between March 1993 and September 2004, 21
onsecutive patients with PMNSGCT were enrolled.
he trial was closed and the analyses performed after
he ﬁrst step because of slow recruitment. Median age
as 29 years (range, 19-55 years). Eight patients
38%) had lung metastases. Clinical features are sum-
arized in Table 1. Surgery at diagnosis was per-
ormed in 6 patients but was radical in only 2 cases. All
ut 2 patients received 4 courses of PEB chemother-
py; bleomycin was substituted for ifosfamide in 2
atients according to the VIP regimen. Two patients
eceived an additional PEB course and 1 patient an
dditional VIP course, instead of the standard 4
ourses, with the purpose of further decreasing resid-
al disease; 1 patient received only 1 PEB course
ecause of PD. Residual surgery after induction che-
otherapy was performed in 6 patients. PBPCs were
obilized with cyclophosphamide plus G-CSF (n 	 4),
-CSF alone (n 	 2), etoposide plus G-CSF (n 	 1),
able 1. Patient Characteristics at Diagnosis
Characteristic n %
atients 21
ge, years
Median (range) 29 (19-55)
etastatic sites
Lung 8 38
Central nervous system 1 5
Other (pleura, pericardium) 2 10
erum tumor markers
Raised AFP (>7 IU/mL) 14* 70
Median (range) 2618 (184-19 920)
Raised -hCG (>5 IU/L) 10† 56
Median (range) 94 (8-1 099 770)
Raised LDH (>243 IU/L) 9‡ 60
Median (range) 1264 (438-2959)
One patient not assessable.
Three patients not assessable.(Six patients not assessable.isplatin and etoposide plus G-CSF (n 	 1), and pacli-
axel, ifosfamide, and cisplatin plus G-CSF (n 	 1).
obilization with G-CSF alone was repeated in 2
atients because of infectious contamination of the
rst collection in 1 patient and poor mobilization after
yclophosphamide in the other. One patient received
DCT with carboplatin alone, at the dose corre-
ponding to Area Under Plasma Concentration Curve
n days 6 to 3, because he had received an addi-
ional ﬁfth PEB course as induction chemotherapy
nd etoposide 2.5 g/m2 as mobilization. A median
ose of 4.8  106 CD34 cells/kg (range, 2.0-8.8)
as administered. Treatment regimens are listed in
able 2.
esponse and Survival
After induction and residual surgery, 4 patients
chieved cCR (19%), 1 achieved pCR (5%), 2 achieved
CR (10%), 4 were PRm (19%), 1 was PRm (5%); 2
ad SD (10%) and 7 (33%) showed PD.
Twelve patients (57%) did not undergo HDCT: 7
atients due to PD after induction regimen, 2 due to
umultuous PD with poor physical condition during
obilization after initial CR to induction chemother-
py, 1 with SD after induction regimen but with poor
erformance status, 1 due to poor mobilization, and 1
ecause of an unwillingness to undergo HDCT.
Nine patients (43%) underwent HDCT. At the time
f HDCT, 2 patients were in cCR, 1 was in pCR, 1 was
n sCR, 3 were PRm, 1 was PRm, and 1 had SD.
After HDCT, 7 of 9 (78%) assessable patients
ere in CR (including 3 in pCR after subsequent
esidual thoracic surgery performed in 4 patients); 1
atient was in PRm (but a viable tumor was disclosed
y subsequent residual thoracic surgery); and 1 patient
ad PD. Among the 7 complete responders to
DCT, 4 underwent transplantation in CR, 2 in
Rm, and 1 in SD; 3 of them (43%) had lung
etastases.
Different salvage chemotherapy regimens were
dministered after induction or HDCT failure; these
ncluded etoposide, ifosfamide, vinblastine, paclitaxel,
emcitabine, and doxorubicin but in all cases resulted
n PD and subsequent progression-related deaths.
OS and PFS curves are shown in Figures 1 and 2,
espectively. OS and PFS at 3 years were 41% (SE,
1.1%) and 43% (SE, 10.8%), respectively. Median
S time was 19 months and median PFS was 10
onths. With a median follow-up of 52 months
range, 15-71 months), 8 patients are alive (38%), 7
ith durable CR and 1 with PRm. The remaining 13
atients (62%) died from PD. All but 1 of 9 patients
89%) who underwent HDCT are alive and in disease
emission, with a median follow-up of 52 months
range, 15-71 months). Of 5 patients who did not
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G. L. Banna et al.1088eceive HDCT despite no evidence of PD after in-
uction chemotherapy (including 2 with cCR after
nduction chemotherapy but with PD during mobili-
able 2. Results of Induction Treatment and High-Dose
hemotherapy
Characteristic n %
urgery at diagnosis 6 29
hemotherapy
PEB 19
VIP 2
esponse after induction/residual
surgery*
cCR 4 19
pCR 1 5
sCR 2 10
PRm 4 19
PRm 1 5
SD 2 10
PD 7 33
D34 mobilization
Cyclophosphamide 4.5 g/m2 4
G-CSF 10 g/kg per day alone 2†
Etoposide/PE/TIP 1/1/1
DCT
CARBOPEC 8 43
CarboAUC24 1
D34 cell dose, median (range) 4.8  106 kg (2.0-8.8)
isease status before HDCT
cCR 2 22
pCR 1 11
sCR 1 11
PRm 3 33
PRm 1 11
SD 1 11
isease status after
HDCT/residual surgery‡
cCR 4 44
pCR 3 33
PRm 1§ 11
PD 1 11
ollow-up (mo)
Median (range) 52 (15-71)
Alive and disease-free 8 38
Died 13 62
EB indicates cisplatin, etoposide, bleomycin; VIP 	 etoposide,
ifosfamide, cisplatin; cCR	 clinical complete remission; pCR	
pathologic CR; sCR 	 surgical CR; PRm 	 partial remission
with negative tumor markers; PRm 	 partial remission with
positive tumor markers; SD 	 stable disease; PD 	 progressive
disease; G-CSF 	 granulocyte colony-stimulating factor; PE 	
cisplatin, etoposide; TIP 	 paclitaxel, ifosfamide, cisplatin;
CARBOPEC 	 high doses of carboplatin, etoposide, cyclo-
phosphamide; CarboAUC24 	 carboplatin at the dose corre-
sponding to AUC 24; HDCT 	 high-dose chemotherapy.
Residual surgery after induction chemotherapy was performed in 6
patients.
Includes 1 poor mobilizer and 1 patient with contaminated yield
after cyclophosphamide.
Responses after HDCT and residual surgery performed in 4 pa-
tients.
Patient underwent residual thoracic surgery with evidence of via-
ble tumor.ation), 4 died of disease. gDCT Toxicity
No toxic deaths occurred. Median durations of G4
eutropenia and thrombocytopenia were 9 days (range,
-12 days) and 6 days (range, 4-9 days), respectively. All
ut 1 patient developed neutropenic fever that re-
olved in all cases with antibiotics. Seven patients
eveloped grade 3-4 mucositis, which required opiate
nalgesics and parenteral nutrition. Most patients had
ausea, vomiting, and diarrhea, which were controlled
ith medication. No other grade 3-4 toxicities and/or
ajor complications were observed. No cases of sec-
ndary acute leukemia and/or other neoplasms have
een observed.
ISCUSSION
HDCT based on carboplatin and etoposide is ac-
ively investigated in patients with germ cell tumor
nd poor prognostic features [4,5].
In this study, we evaluated the feasibility and
ctivity of a single course of early HDCT with
ARBOPEC after induction chemotherapy for pa-
ients with PMNSGCT. Of 21 patients who started
nduction chemotherapy, only 9 (43%) received
DCT. Twelve patients were not treated with
DCT mainly due to PD and poor physical condi-
ion. A harvesting failure rate of 25%-30% was pre-
iously reported in patients with heavily pretreated
erm cell tumor [13]. In our study, patients with
MNSGCT were not heavily pretreated, but patients
id not receive HDCT due to early PD during/after
nduction chemotherapy.
The role of HDCT in patients with PMNSGCT
as very difﬁcult interpret in our study, mainly due to
atient selection. Moreover, HDCT in patients who
o not achieve a CR or PRm status after 3-4 courses
f an induction chemotherapy could be considered as
second-line treatment, and very poor results have
een reported with HDCT in this setting for patients
ith PMNSGCT [9]. We reported 3-year OS and
FS of 41% and 43%, respectively, which did not
ppear to differ from those reported by other investi-
ators who used conventional treatments [1,2,4].
owever, all but 1 of 9 patients (89%) who underwent
DCT are alive and in disease remission with a me-
ian follow-up of 52 months (range, 15-71 months),
hereas 4 of 5 patients (80%) who had disease re-
ponse after induction treatment but did not undergo
DCT relapsed and died from PD. Thirteen patients
62%) progressed and died despite different salvage
hemotherapy regimens administered.
In our series, 6 patients underwent early residual
urgery, performed after standard-dose chemother-
py, thus possibly delaying the administration of
DCT. Instead, 4 patients underwent residual sur-
ery after HDCT. Of note, 5 of 6 patients who un-
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High-Dose Chemotherapy for Mediastinal Germ Cell Tumors 1089erwent early residual surgery had histologic evidence
f residual disease, whereas 3 of 4 patients who un-
erwent residual surgery after HDCT were in pCR.
esidual surgery has an important role in the treat-
ent of PMNSGCT, although no optimal timing has
een established in HDCT programs [14].
Our ﬁndings may support the role of dose inten-
ity in the treatment of PMNSGCT for the mainte-
ance and induction (3 of 9 patients who underwent
DCT were not in CR or PRm) of disease response;
arlier HDCT administration and performing residual
Figure 1. ProbabFigure 2. Probability of progurgery after earlier HDCT may be suggested and con-
idered for further evaluation in prospective studies.
Comparison of our study with other similar trials
s limited by few reports on HDCT for these patients.
oreover, most investigators included few cases of
MNSGCT in larger groups of patients with poor
rognosis [1].
Decatris et al [7] reported 4-year PFS and OS of
2%, and 25%, respectively, for patients with
MNSGCT who were treated with HDCT after
-4 courses of PEB. A recent analysis of the Euro-
overall survival.ression-free survival.
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G. L. Banna et al.1090ean Bone Marrow Transplantation Solid Tumors
orking Party [8] showed a disease-free survival of
4% in the 11 patients with PMNSGCT who re-
eived early HDCT. However, in these trials, data
eferred only to patients with responsive disease
ho had undergone HDCT, but no data were avail-
ble about patients who started the induction regi-
en but did not receive HDCT [7-9].
The only available phase III trial in patients with
oor prognosis, which was presented only as an ex-
ended abstract, showed no advantage for the HDCT
rm, but lacked data on patients with PMNSGCT
15].
Bokemeyer et al [6] used a matched-pair analysis
mong 147 patients with poor prognosis who were
reated with a single course of mobilizing chemother-
py and 3-4 courses of high-dose cisplatin, etoposide,
nd ifosfamide and 309 patients who were treated with
tandard-dose PEB or VIP chemotherapy and reported a
igniﬁcant improvement in PFS (75% versus 59%, P 	
.0056) and OS (82% versus 71%, P 	 0.0184). How-
ver, no data on patients with PMNSGCT, which rep-
esented 10% of all cases, were available.
Recently, multicycle upfront HDCT has shown
nteresting results in patients with poor prognosis and
-year PFS and disease-speciﬁc survival rates of 69%
nd 79% [16]. In a subgroup with PMNSGCT, these
esults were substantially similar, with 2-year PFS and
S rates of 64 and 68%, respectively [10]. This strat-
gy was explored in a phase I-II study in 221 patients
ith Indiana advanced disease or International Germ
ell Cancer Collaborative Group poor prognosis cri-
eria and consisted of the administration of 3-4 se-
uential cycles of high-dose VIP (cisplatin, etoposide,
nd ifosfamide) at 6 consecutive dose levels after 1
ycle of standard induction/mobilization VIP [16].
he results observed in the subgroup with PMNS-
CT might indicate an approximately 15% survival
mprovement compared with data of an international
atabase analysis including 253 patients with PMNS-
CT treated with conventional chemotherapy [10].
Other possible strategies to improve outcome of
atients with PMNSGCT consist of intensive chemo-
herapeutic regimens such as intensive induction and
equential, alternating, or dose-dense chemotherapy,
nd the addition of new active drugs (eg, paclitaxel)
17-19]. Recently, Christian et al [20] reported the
esults of an intensive induction chemotherapy with
leomycin, vincristine, and cisplatin alternating with
EB (CBOP/PEB regimen) with a 3-year OS of 77%
or patients with PMNSGCT. However, nearly 50%
f patients with PMNSGCT did not receive a com-
lete course of CBOP/BEP and toxicities were con-
iderable.
In conclusion, a single course of HDCT after
rimary chemotherapy appeared to be inapplicable in
ost of our patients with PMNSGCT, mainly due to 1arly PD. Patients with PMNSGCT have a risk of
0%-35% of early PD during or after induction che-
otherapy [3-5]. This issue should be considered in
he analysis of retrospective series and in the design of
linical trials with HDCT in PMNSGCT. Earlier
DCT administration followed by residual surgery
hould be considered for further evaluation in pro-
pective studies. Recently, multicycle upfront HDCT
as shown interesting results in these patients. This
trategy is currently being investigated in 2 ongoing,
hase III, randomized studies in Europe and the
nited States. Results of these trials may better deﬁne
he role of HDCT in these patients.
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